Pulmonem
Pulmonem Inc. is a pioneering biotechnology company dedicated to advancing therapeutic solutions for Acute Respiratory Distress Syndrome (ARDS). The company is focused on developing innovative treatments, including PULM-001, a drug designed to combat infectious diseases and mitigate lung inflammation. Pulmonem has obtained IND approval for Phase 3 clinical trials in the US and Canada, with plans to expand to India. The company is also exploring solutions for pediatric markets and alternative delivery systems. Its mission is to develop novel therapies to address critical gaps in respiratory medicine and improve patient survival and outcomes.
Industries
Nr. of Employees
small (1-50)
Pulmonem
Patents
Method of treating a person afflicted with a respiratory condition and pharmaceutical formulation including dapsone
US-12396967-B2
View DetailsMethod of treating a person afflicted with COVID-19 and pharmaceutical formulation including dapsone
US-11826323-B2
View Details
Method of treating a person afflicted with a respiratory condition and pharmaceutical formulation including dapsone
US-12396967-B2
View DetailsMethod of treating a person afflicted with COVID-19 and pharmaceutical formulation including dapsone
US-11826323-B2
View DetailsProducts
Reformulated generic oral anti-inflammatory/immunomodulatory therapeutic (dapsone-based) for severe respiratory inflammation
A patented reformulation of an established generic small-molecule anti-inflammatory and antibacterial intended to reduce pulmonary inflammation, prevent progression to ARDS, and decrease hospitalizations, ICU admissions, mechanical ventilation, and mortality in severe respiratory infections.
Reformulated generic oral anti-inflammatory/immunomodulatory therapeutic (dapsone-based) for severe respiratory inflammation
A patented reformulation of an established generic small-molecule anti-inflammatory and antibacterial intended to reduce pulmonary inflammation, prevent progression to ARDS, and decrease hospitalizations, ICU admissions, mechanical ventilation, and mortality in severe respiratory infections.
Services
Operational support for multicentre Phase 3 randomized clinical trials including site coordination, patient recruitment, and collaboration with academic sponsors and CROs.
Establishment of manufacturing agreements and supply-chain arrangements to enable rapid, high-volume production of oral tablet therapeutics.
Support for preparing and filing regulatory submissions for clinical trials and maintaining compliance with regulatory agencies.
Patent filing and IP strategy for reformulated generics and novel formulations.
Operational support for multicentre Phase 3 randomized clinical trials including site coordination, patient recruitment, and collaboration with academic sponsors and CROs.
Establishment of manufacturing agreements and supply-chain arrangements to enable rapid, high-volume production of oral tablet therapeutics.
Support for preparing and filing regulatory submissions for clinical trials and maintaining compliance with regulatory agencies.
Patent filing and IP strategy for reformulated generics and novel formulations.
Expertise Areas
- Clinical trial management and execution (Phase 3)
- Drug repurposing and reformulation
- Regulatory submissions and compliance (IND/Phase 3)
- GMP manufacturing scale-up for oral solids
Key Technologies
- Reformulation of small-molecule generics (oral tablets)
- Alternative delivery systems (nasal spray, inhaler, liquid formulations)
- Remote e-consent and patient monitoring platforms
- Large-scale GMP tablet manufacturing